These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9331514)

  • 1. Side effects of high-dose intravenous immunoglobulins.
    Stangel M; Hartung HP; Marx P; Gold R
    Clin Neuropharmacol; 1997 Oct; 20(5):385-93. PubMed ID: 9331514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
    Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
    J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases.
    Hoffmann JHO; Enk AH
    J Dtsch Dermatol Ges; 2017 Dec; 15(12):1211-1226. PubMed ID: 29228499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.
    Vecchietti G; Kerl K; Prins C; Kaya G; Saurat JH; French LE
    Arch Dermatol; 2006 Feb; 142(2):213-7. PubMed ID: 16490849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies.
    Brannagan TH
    Neurology; 2002 Dec; 59(12 Suppl 6):S33-40. PubMed ID: 12499469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical decisions in selecting an intravenous immunoglobulin product.
    Gelfand EW
    J Infus Nurs; 2005; 28(6):366-74. PubMed ID: 16304494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.
    Stangel M; Kiefer R; Pette M; Smolka MN; Marx P; Gold R
    J Neurol; 2003 Jul; 250(7):818-21. PubMed ID: 12883923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
    Rigas M; Tandan R; Sterling RJ
    J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk.
    Dantal J
    Am J Nephrol; 2013; 38(4):275-84. PubMed ID: 24051350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of high-dose intravenous immunoglobulin (IVIG) in a 5% and a 10% solution does not reveal a significantly different spectrum of side-effects.
    Rappold LC; Denk K; Enk AH; Hadaschik EN
    J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):e186-e188. PubMed ID: 26551028
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse events associated with intravenous immunoglobulin therapy.
    Hamrock DJ
    Int Immunopharmacol; 2006 Apr; 6(4):535-42. PubMed ID: 16504916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin: adverse effects and safe administration.
    Orbach H; Katz U; Sherer Y; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
    Barsheshet A; Marai I; Appel S; Zimlichman E
    Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view.
    Ruetter A; Luger TA
    Am J Clin Dermatol; 2004; 5(3):153-60. PubMed ID: 15186194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.
    Wittstock M; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V75-9. PubMed ID: 16998759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
    Rütter A; Luger TA
    J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura.
    Bierling P; Godeau B
    Hum Immunol; 2005 Apr; 66(4):387-94. PubMed ID: 15866702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intravenous immunoglobulins for lupus nephritis--a salvage immunomodulation.
    Rauova L; Lukac J; Levy Y; Rovensky J; Shoenfeld Y
    Lupus; 2001; 10(3):209-13. PubMed ID: 11315354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases.
    Katz U; Shoenfeld Y; Zandman-Goddard G
    Curr Pharm Des; 2011; 17(29):3166-75. PubMed ID: 21864262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic toxicities associated with intravenous immunoglobulin therapy.
    Baxley A; Akhtari M
    Int Immunopharmacol; 2011 Nov; 11(11):1663-7. PubMed ID: 21843660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.